Unknown

Dataset Information

0

The Safety and Clinical Validity of Endoscopic Submucosal Dissection for Early Gastric Cancer in Patients Aged More Than 85 Years.


ABSTRACT: Endoscopic submucosal dissection (ESD) is a safe and minimally invasive method for the treatment of early gastric cancer (EGC). However, whether ESD for EGC is also safe and feasible in patients aged ≥85 years is unclear. The patients enrolled in this study were divided into three groups: age ≥85 years (44 patients, 49 lesions), age 65-84 years (624 patients, 687 lesions), and age ≤64 years (162 patients, 174 lesions). We evaluated the incidence of adverse events (AEs) and overall survival (OS) and disease-specific survival (DSS). We analyzed the factors that had a significant impact on the prognosis of patients aged ≥85 years. No significant differences were found in the incidence of AEs among the three groups (p = 0.612). The OS was significantly lower in patients aged ≥85 years (p < 0.001). Conversely, DSS was not significantly worse in patients aged ≥85 years (p = 0.100). The poor Geriatric Nutritional Risk Index correlated with poor prognosis in patients aged ≥85 years (p < 0.001). ESD is a safe and valid treatment for EGC in patients aged ≥85 years. However, the indications should be carefully decided because it is difficult to estimate the survival contribution of ESD for EGC in patients aged ≥85 years, especially in those with poor nutritional status.

SUBMITTER: Yoshikawa T 

PROVIDER: S-EPMC9323451 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


Endoscopic submucosal dissection (ESD) is a safe and minimally invasive method for the treatment of early gastric cancer (EGC). However, whether ESD for EGC is also safe and feasible in patients aged ≥85 years is unclear. The patients enrolled in this study were divided into three groups: age ≥85 years (44 patients, 49 lesions), age 65−84 years (624 patients, 687 lesions), and age ≤64 years (162 patients, 174 lesions). We evaluated the incidence of adverse events (AEs) and overall survival (OS)  ...[more]

Similar Datasets

| S-EPMC7692251 | biostudies-literature
| S-EPMC6754868 | biostudies-literature
| S-EPMC7290846 | biostudies-literature
| S-EPMC5523312 | biostudies-other
| S-EPMC4875835 | biostudies-literature
| S-EPMC6895728 | biostudies-literature
| S-EPMC11653160 | biostudies-literature
| S-EPMC11604307 | biostudies-literature
| S-EPMC8560818 | biostudies-literature
| S-EPMC8577659 | biostudies-literature